ADA (American Diabetes Association) June 20-23 Obesity Medicines Novo Nordisk Posters and Talks
Novo CagriSema CagriSema is an investigational medication being developed by Novo Nordisk for the treatment of obesity and type 2 diabetes. It is a fixed-dose combination of two drugs: Cagrilintide: An amylin analog that helps regulate appetite and reduce food intake Semaglutide: A glucagon-like peptide-1 (GLP-1) receptor agonist that improves blood sugar control and promotes weight loss. CagriSema is designed […]
Renewing the Ozempic Patent in Canada Costs Very Little. Surprisingly, Novo Nordisk Has Chosen Not to
Novo Nordisk is the Danish pharmaceutical company that developed semaglutide, the active ingredient in the widely-used Ozempic medication. Notably, the company has failed to pay the maintenance fee for its patent for several years. A million-worth oversight. According to a Science article, Novo Nordisk hasn’t paid the maintenance fee for the semaglutide patent, which currently […]
GLP-1 Drugs Like Ozempic Are Widely Popular. Here Are Side Effects You Should Know About
Glucagon-Like-Peptide-1 Agonists, like Ozempic, have become extremely popular for weight loss. Here are some of the side effects you should know about.
Oral Semaglutide: Trends Suggest Potential Kidney Benefits
While the renal benefits of oral semaglutide vs placebo in the SOUL trial didn’t match the effects seen with the injectable formulation in the FLOW trial, the observed trends suggest improvements. Medscape Medical News
Lark Health unveils LarkVantage, an AI-powered tool to manage GLP-1 costs – Fierce Healthcare
Lark Health unveils LarkVantage, an AI-powered tool to manage GLP-1 costs Fierce Healthcare
Bariatric Surgery Beats GLP-1 RAs for Sustained Weight Loss
Bariatric surgery is associated with a significantly greater long-term weight loss than treatment with GLP-1 receptor agonists, a new head-to-head real-world study finds. Medscape Medical News
Uncovering unexpected impacts of popular GLP-1 diabetes drugs
GLP-1 drugs show promise in diabetes management, offering heart and kidney benefits, but also highlight the need for vigilance regarding new health risks.
STAT+: Eli Lilly to buy gene-editing biotech Verve for up to $1.3 billion
Eli Lilly said Tuesday that it will acquire Verve Therapeutics, a biotech developing gene-editing therapies for cardiovascular disease. Lilly will acquire Verve for $10.50 per share, a premium of nearly 70% to the biotech’s share price at Monday’s close. The deal also includes an additional payment of $3 per share contingent on the first patient […]
Kerry Group gauges probiotic potential in the age of GLP-1
As GLP-1 weight loss drugs become more common, managing side effects has emerged as key to adherence. A Kerry Group consumer perception study suggests its BC30 Probiotic may help reduce digestive discomfort linked to these medications.
Eli Lilly, Juvena Therapeutics Partner to Develop Muscle-Boosting Drugs Using AI Platform
Eli Lilly and Company (NYSE:LLY) is one of the best stocks to buy for beginners now. On June 11, Eli Lilly announced a partnership with Juvena Therapeutics to develop new muscle-boosting drugs. The collaboration is valued at over $650 million, with the majority of this sum tied to the achievement of specific development and commercialization […]